TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06435676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Single dose escalation of HRS9531 tablets in healthy subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo in healthy adults

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Multiple dose escalation of HRS9531 tablets in healthy subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo in healthy adults
Study: NCT05708144

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICG-SG incubation solution
Description: The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
Study: NCT05308056

Intervention type: DEVICE
Intervention: Depth of anesthesia monitor, SedLine® (Masimo, Irvine, CA, USA)
Description: The device monitors the patient's electroencephalogram using electrodes applied to the forehead.
Study: NCT05372783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-9199
Description: STI-9199 is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study: NCT06034561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.
Study: NCT05981820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: To observe the effects of creatine in the study, 10 g of creatine supplementation was taken only on training days during the study period. Participants used 10 g of creatine monohydrate by dissolved in 200 ml of water. Creatine supplementation was taken in two doses of five grams, 30 minutes before and after training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT training
Description: In the first three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT training
Description: In the first three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets
Study: NCT06227156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection
Description: 2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle
Study: NCT05010044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based cognitive therapy (MBCT)
Description: Mindfulness- Based Cognitive Therapy (MBCT) It involves practicing to be present 'in the moment' and an attitude of non- judgmental acceptance with the aim to maintain awareness, disengaging oneself from strong attachment and thereby developing a greater sense of emotional balance and well-being.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antipsoriatic treatment
Description: The routine drug therapy for psoriasis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antipsoriatic treatment
Description: The routine drug therapy for psoriasis.
Study: NCT04725448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg, ivgtt, d1, every 3 weeks until disease progress or intolerable toxicity, up to 2 years of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg, ivgtt, d1, every 3 weeks, up to 2 years of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 260mg/m2,d1 or 130mg/m2,d1,8, ivgtt, every 3 weeks, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=4～5, d1, ivgtt, every 3 weeks, up to 6 cycles
Study: NCT04917653

Intervention type: DEVICE
Intervention: Heart rhythm monitoring with wearable device
Description: The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.

Intervention type: OTHER
Intervention: Blood samples and biomarkers
Description: Several blood samples will be collected during the study protocol in pre-defined times before and after the cardioversion intervention.~Atrial peptides and cardiac troponins will be analyzed and kinetics estimated to predict the duration of early-onset AF period.
Study: NCT05632224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: The drug is given 1 hour before the start of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: The drug is given 10 minutes before the patients's extubation
Study: NCT02601391

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapting STEPPS within forensic inpatient services.
Description: This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
Study: NCT04412681

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Enhanced PE Screening
Description: To better identify women at risk for pre-eclampsia during pregnancy.
Study: NCT05789160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress
Description: Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study: NCT05425719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102
Description: 18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102
Description: 18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Description: On treatment day, participants had a transdermal sensor placed on their upper chest, and the MediBeacon Transdermal GFR Measurement System was initiated to collect background fluorescence. After collection of background fluorescence, participants received a single dose of MB-102.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Description: On treatment day, participants had a transdermal sensor placed on their upper chest, and the MediBeacon Transdermal GFR Measurement System was initiated to collect background fluorescence. After collection of background fluorescence, participants received a single dose of MB-102.
Study: NCT05169385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent SMART
Description: Parent SMART experimental intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Residential treatment as usual
Study: NCT05817825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart IOP Intervention
Description: Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Coach
Description: Peer recovery coach, an individual in sustained recovery (\>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
Study: NCT06492967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic Lifestyle Intervention
Description: Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexible Lifestyle Intervention
Description: Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
Study: NCT06322212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.
Study: NCT00429754

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Study: NCT06075875

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mixed animal and vegetable proteins
Description: mixed animal and vegetable proteins in the standard ratio (2/3:1/3; 60%:40% respectively) present in the nutritional menu over all hospitals in the general organization of teaching hospitals and institutes GOTHI; Egypt= as a control group) and continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pure vegetable proteins
Description: pure vegetable proteins continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).
Study: NCT05055076

Intervention type: DEVICE
Intervention: PODEYE TORIC
Description: Patients will be contacted consecutively and will be enrolled after the patient informed leaflet has been given to them and after obtaining their consent to the scientific use of their data collected retrospectively (preoperative, surgery, postoperative routine visits). Patients will only be enrolled after the routine 4-6 months visit has been performed.
Study: NCT05239650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: 1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: 1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
Study: NCT05871112

Intervention type: OTHER
Intervention: Use of dynamic tensioner
Description: Assessment of femoral component rotation with a use of a dynamic tensioner in extension and 90 degrees of flexion. The tensioner was put between tibial plane cut and posterior condyles of the femur and tensioned to the same thickness of insert as in the full extension
Study: NCT05908669

Intervention type: DIAGNOSTIC_TEST
Intervention: Deuterium metabolic imaging
Description: MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
Study: NCT05161585

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA dynamic monitoring
Description: ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total.
Study: NCT04920916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline.
Study: NCT04677491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ospemifene 60 mg
Description: Ospemifene vs placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: fMRI experiments
Description: Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: fMRI experiments
Description: Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
Study: NCT04203316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given PO
Study: NCT05691192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Leisure Activities
Description: Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
Study: NCT05329337

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Sixteen mL of blood will be collected on EDTA for the purpose of this study

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Sixteen mL of blood will be collected on EDTA for the purpose of this study
Study: NCT05413629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based patient education for the intrauterine insemination (IUI) treatment process
Description: Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based patient education for the intrauterine insemination (IUI) treatment process
Description: Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.
Study: NCT05443685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: Subjects 10-50 years old will be administered ADX-629 250 mg tablets twice daily.~Subjects 5-9 years old will be administered ADX-629 125 mg tablets twice daily.
Study: NCT06048835

Intervention type: DEVICE
Intervention: Blood sample
Description: For each patient, a 15 ml EDTA blood sample will be collected at different time-points
Study: NCT06000917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
Description: Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles.~Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.~Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.~Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration
Study: NCT06048835

Intervention type: DEVICE
Intervention: Blood sample
Description: For each patient, a 15 ml EDTA blood sample will be collected at different time-points

Intervention type: DEVICE
Intervention: Blood sample
Description: For each patient, a 15 ml EDTA blood sample will be collected at different time-points
Study: NCT05419752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioceramic sealer
Description: bioceramic based obturating sealer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTA
Description: MTA based obturating sealer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resin sealer
Description: resin based obturating sealer
Study: NCT05572840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and activities
Description: The training program consists of two modules. The 1st module consists of a theoretical lecture (powerpoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (powerpoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks).
Study: NCT05181592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)
Study: NCT06453798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical spine exercises
Description: Cervical spine exercise training is a method to improve the neck function through the patient's self-exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical spine exercises
Description: Cervical spine exercise training is a method to improve the neck function through the patient's self-exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromobilization
Description: Neuromobilization is a technical technique for rehabilitation therapists to loosen the trapped nerves of patients with professional methods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromobilization
Description: Neuromobilization is a technical technique for rehabilitation therapists to loosen the trapped nerves of patients with professional methods.
Study: NCT05520658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined digoxin and furosemide
Description: one session every 2 weeks for maximum 6 sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 fluorouracil
Description: 5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
Study: NCT04575519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA group
Description: Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBU group
Description: Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC TB
Description: Standard of Care Tuberculosis treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC TB
Description: Standard of Care Tuberculosis treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC TB
Description: Standard of Care Tuberculosis treatment
Study: NCT05244499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based leadership training
Description: 7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: 7-modules online training over six months. Independent reading only.
Study: NCT05820620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB block
Description: Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Control Group + Patient Control Analgesia (PCA)